Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
- Published In:
- Pharmacotherapy, 33(6), 627-38 (2013)
- Database ID:
- RPEP-02235
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02235APA
Minze, Molly G; Klein, Mary S; Jernigan, Michelle J; Wise, Stephen L; Frugé, Kristian. (2013). Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.. Pharmacotherapy, 33(6), 627-38. https://doi.org/10.1002/phar.1240
MLA
Minze, Molly G, et al. "Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.." Pharmacotherapy, 2013. https://doi.org/10.1002/phar.1240
RethinkPeptides
RethinkPeptides Research Database. "Once-weekly exenatide: an extended-duration glucagon-like pe..." RPEP-02235. Retrieved from https://rethinkpeptides.com/research/minze-2013-onceweekly-exenatide-an-extendedduration
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.